Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 4

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 4
---
              (C$) |        Year ended 
 December 31, 2022 
              (C$) |
|:----------------------------|-------------------------------------:|------------------:|------------------:|------------------:|
| As at end of period         |                               1.3499 |            1.4389 |            1.3226 |            1.3544 |
| Low for the period          |                               1.3316 |            1.3316 |            1.3128 |            1.2451 |
| High for the period         |                               1.3858 |            1.4416 |            1.3875 |            1.3856 |
| Average rate for the period |                               1.3604 |            1.3698 |            1.3497 |            1.3013 |

On March 6, 2025, the daily average exchange rate for Canadian dollars in terms of the U.S. dollar, as quoted by the Bank of Canada, was $1.00 = C$1.4309.

<div align='center'>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</div>

This offering circular includes forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this offering circular regarding our strategy, future operations, regulatory process, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "believe", "anticipate", "intend", "expect", "target", "goal", "estimate", "plan", "assume", "may", "will", "predict", "project", "would", "could" and similar expressions or the negative of such terms are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The forward-looking statements in this offering circular include, but are not limited to, statements about:

•our financial results, including our ability to generate earnings and achieve and sustain profitability, which may vary significantly from forecasts and from period to period;

•the progress, timing and completion of our research, development and preclinical studies and clinical trials for our products and product candidates;

•our ability to market, commercialize, achieve market acceptance for and sell our products and product candidates;

•our ability to develop, manage and maintain our direct sales and marketing organizations;

•our estimates regarding